Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 2,483,500 | 2,493,200 | 2,374,800 | 2,302,700 | 2,334,300 |
| Cost of Goods | 318,700 | 308,600 | 266,900 | 283,300 | 289,400 |
| Gross Profit | 2,164,800 | 2,184,600 | 2,107,900 | 2,019,401 | 2,044,900 |
| Operating Expenses | 1,127,400 | 1,158,800 | 1,329,800 | 986,200 | 918,600 |
| Operating Income | 1,038,100 | 1,026,400 | 779,000 | 1,033,500 | 1,126,700 |
| Interest Expense | 10,900 | 11,200 | 11,400 | 11,600 | 13,700 |
| Other Income | 152,000 | 146,300 | 123,900 | 54,900 | 63,400 |
| Pre-tax Income | 1,179,200 | 1,161,500 | 891,500 | 1,076,800 | 1,176,400 |
| Income Tax | 143,900 | 245,800 | 191,700 | 257,900 | 245,900 |
| Net Income Continuous | 1,035,300 | 915,700 | 699,800 | 818,900 | 930,500 |
| Net Income | $1,035,300 | $915,700 | $699,800 | $818,900 | $930,500 |
| EPS Basic Total Ops | 4.01 | 3.55 | 2.72 | 3.18 | 3.63 |
| EPS Basic Continuous Ops | 4.01 | 3.55 | 2.72 | 3.19 | 3.63 |
| EPS Diluted Total Ops | 3.97 | 3.52 | 2.69 | 3.14 | 3.59 |
| EPS Diluted Continuous Ops | 3.97 | 3.52 | 2.69 | 3.15 | 3.59 |
| EBITDA(a) | $1,080,200 | $1,067,800 | $817,800 | $1,071,900 | $1,163,400 |